간문부 담관암에서 광역학 치료의 장기 성적 및 생존율 향상에 미치는 인자 = The Long-term Outcome and Predictors for Increased Survival after PDT for Hilar Cholangiocarcinoma

다국어 초록 (Multilingual Abstract)

Background/Aims: Photodynamic therapy (PDT) has a promising effect on nonresectable cholangiocarcinoma (CC) but its long term data is not yet available. This study examined the long term outcome and factors associated with increased survival after performing PDT for hilar cholangiocarcinoma.
Methods: A list of 393 patients with a diagnosis of hilar CC was retrieved from the database of Soonchunhyang University Hospital (Seoul, Korea) and these patients were seen from January 1, 2001, to April 1, 2010. We retrospectively reviewed the records of 74 patients who underwent PDT in addition to biliary stenting with/without chemoradiation.
Results: The median overall survival from the date of diagnosis to death or to the last follow-up was 11.7 months (range: 2.2∼78.4). After performing PDT, a complete remission was observed in 1.3% (1/74) of the patients who had a superficial depth of tumor without lymph node involvement. On multivariate analysis using the Cox regression model, increasing the time to treatment after the diagnosis was a statistically significant predictor of shorter survival after PDT [Odds ratio: 3.25, 95% confidence interval (CI): 1.90∼4.71, p=0.034].
Conclusions: Although PDT does not prevent progression of CC, it appears to control the cholestasis. The early treatment of PDT after the diagnosis showed a survival benefit for patients with advanced hilar CC.

다국어 초록 (Multilingual Abstract)

Background/Aims: Photodynamic therapy (PDT) has a promising effect on nonresectable cholangiocarcinoma (CC) but its long term data is not yet available. This study examined the long term outcome and factors associated with increased survival after performing PDT for hilar cholangiocarcinoma.
Methods: A list of 393 patients with a diagnosis of hilar CC was retrieved from the database of Soonchunhyang University Hospital (Seoul, Korea) and these patients were seen from January 1, 2001, to April 1, 2010. We retrospectively reviewed the records of 74 patients who underwent PDT in addition to biliary stenting with/without chemoradiation.
Results: The median overall survival from the date of diagnosis to death or to the last follow-up was 11.7 months (range: 2.2∼78.4). After performing PDT, a complete remission was observed in 1.3% (1/74) of the patients who had a superficial depth of tumor without lymph node involvement. On multivariate analysis using the Cox regression model, increasing the time to treatment after the diagnosis was a statistically significant predictor of shorter survival after PDT [Odds ratio: 3.25, 95% confidence interval (CI): 1.90∼4.71, p=0.034].
Conclusions: Although PDT does not prevent progression of CC, it appears to control the cholestasis. The early treatment of PDT after the diagnosis showed a survival benefit for patients with advanced hilar CC

참고문헌 (Reference)

1 Klempnauer J, "What constitutes long-term survival after surgery for hilar cholangiocarcinoma?" 79 : 26-34, 1997

2 Ortner ME, "Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study" 125 : 1355-1363, 2003

3 Vauthey JN, "Recent advances in the management of cholangiocarcinoma" 14 : 109-114, 1994

4 Davids PH, "Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction" 340 : 1488-1492, 1992

5 Shim CS, "Prospective study of the effectiveness of percutaneous transhepatic photodynamic therapy for advanced bile duct cancer and the role of intraductal ultrasonography in response assessment" GEORG THIEME VERLAG KG 37 : 425-433, 2005

6 Prout GR, "Photodynamic therapy with hematoporphyrin derivative in the treatment of superficial transitional-cell carcinoma of the bladder" 317 : 1251-1255, 1987

7 Edell ES, "Photodynamic therapy in the management of early superficial squamous cell carcinoma as an alternative to surgical resection" 102 : 1319-1322, 1992

8 Berr F, "Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival" 31 : 291-298, 2000

9 Pitt HA, "Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival" 221 : 788-797, 1995

10 Zoepf T, "Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy" 100 : 2426-2430, 2005

11 Molt P, "Intraluminal radiation therapy in the management of malignant biliary obstruction" 57 : 536-544, 1986

12 Bismuth H, "Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver" 140 : 170-178, 1975

13 Kremer B, "Impact of staging on treatment of biliary carcinoma" 25 : 92-99, 1993

14 Burke EC, "Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system" 228 : 385-394, 1998

15 Khan SA, "Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document" 51 (51): VI1-9, 2002

16 Prasad GA, "Factors associated with increased survival after photodynamic therapy for cholangiocarcinoma" 5 : 743-748, 2007

17 Cheon YK, "Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy" BLACKWELL PUBLISHING 102 : 2164-2170, 2007

18 Valle J, "ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer" 362 : 1273-1281, 2010

19 Bowling TE, "A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma" 39 : 852-855, 1996